191 related articles for article (PubMed ID: 23840429)
1. Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways.
Saxena R; Chandra V; Manohar M; Hajela K; Debnath U; Prabhakar YS; Saini KS; Konwar R; Kumar S; Megu K; Roy BG; Dwivedi A
PLoS One; 2013; 8(6):e66246. PubMed ID: 23840429
[TBL] [Abstract][Full Text] [Related]
2. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumorigenic action of 2-[piperidinoethoxyphenyl]-3-[4-hydroxyphenyl]-2H-benzo(b)pyran: evidence for involvement of GPR30/EGFR signaling pathway.
Chandra V; Fatima I; Saxena R; Hussain MK; Hajela K; Sankhwar P; Roy BG; Chandna S; Dwivedi A
Gynecol Oncol; 2013 May; 129(2):433-42. PubMed ID: 23402905
[TBL] [Abstract][Full Text] [Related]
4. 2,3-Diaryl-2H-1-benzopyran derivatives interfere with classical and non-classical estrogen receptor signaling pathways, inhibit Akt activation and induce apoptosis in human endometrial cancer cells.
Fatima I; Chandra V; Saxena R; Manohar M; Sanghani Y; Hajela K; Negi MP; Sankhwar PL; Jain SK; Dwivedi A
Mol Cell Endocrinol; 2012 Jan; 348(1):198-210. PubMed ID: 21878365
[TBL] [Abstract][Full Text] [Related]
5. The in vitro and in vivo anti-tumor effect of KO-202125, a sauristolactam derivative, as a novel epidermal growth factor receptor inhibitor in human breast cancer.
Oh M; Lee JY; Shin DH; Park JH; Oian T; Kim HJ; Cho SD; Oh SH; Min YK; Kong G
Cancer Sci; 2011 Mar; 102(3):597-604. PubMed ID: 21205071
[TBL] [Abstract][Full Text] [Related]
6. The anti-proliferative effect of 2-[piperidinoethoxyphenyl]-3-[4-hydroxyphenyl]-2H-benzo(b) pyran is potentiated via induction of estrogen receptor beta and p21 in human endometrial adenocarcinoma cells.
Fatima I; Saxena R; Kharkwal G; Hussain MK; Yadav N; Hajela K; Sankhwar PL; Dwivedi A
J Steroid Biochem Mol Biol; 2013 Nov; 138():123-31. PubMed ID: 23688837
[TBL] [Abstract][Full Text] [Related]
7. Retraction: Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways.
PLOS ONE Editors
PLoS One; 2020; 15(3):e0231282. PubMed ID: 32218596
[No Abstract] [Full Text] [Related]
8. Inhibition of EGF/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells.
Hsieh CY; Tsai PC; Tseng CH; Chen YL; Chang LS; Lin SR
Toxicol In Vitro; 2013 Feb; 27(1):1-10. PubMed ID: 23064031
[TBL] [Abstract][Full Text] [Related]
9. A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells.
Chu B; Liu F; Li L; Ding C; Chen K; Sun Q; Shen Z; Tan Y; Tan C; Jiang Y
Cell Death Dis; 2015 Mar; 6(3):e1686. PubMed ID: 25766325
[TBL] [Abstract][Full Text] [Related]
10. Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.
Nath N; Chattopadhyay M; Rodes DB; Nazarenko A; Kodela R; Kashfi K
Molecules; 2015 Jul; 20(7):12481-99. PubMed ID: 26184135
[TBL] [Abstract][Full Text] [Related]
11. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.
Sarkar S; Mazumdar A; Dash R; Sarkar D; Fisher PB; Mandal M
Cancer Biol Ther; 2010 Apr; 9(8):592-603. PubMed ID: 20139705
[TBL] [Abstract][Full Text] [Related]
12. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways.
Vanderlaag K; Su Y; Frankel AE; Grage H; Smith R; Khan S; Safe S
Breast Cancer Res Treat; 2008 May; 109(2):273-83. PubMed ID: 17624585
[TBL] [Abstract][Full Text] [Related]
13. Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
Nagaria TS; Williams JL; Leduc C; Squire JA; Greer PA; Sangrar W
Neoplasia; 2013 Aug; 15(8):939-51. PubMed ID: 23908594
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of 2-(piperidinoethoxyphenyl)-3-(4-hydroxyphenyl)-2H-benzo(b)pyran (K-1) on human primary endometrial hyperplasial cells mediated via combined suppression of Wnt/β-catenin signaling and PI3K/Akt survival pathway.
Chandra V; Fatima I; Manohar M; Popli P; Sirohi VK; Hussain MK; Hajela K; Sankhwar P; Dwivedi A
Cell Death Dis; 2014 Aug; 5(8):e1380. PubMed ID: 25144715
[TBL] [Abstract][Full Text] [Related]
15. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways.
Chun J; Kim YS
Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
Zhang X; Diaz MR; Yee D
Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
[TBL] [Abstract][Full Text] [Related]
17. Gallic acid abolishes the EGFR/Src/Akt/Erk-mediated expression of matrix metalloproteinase-9 in MCF-7 breast cancer cells.
Chen YJ; Lin KN; Jhang LM; Huang CH; Lee YC; Chang LS
Chem Biol Interact; 2016 May; 252():131-40. PubMed ID: 27087131
[TBL] [Abstract][Full Text] [Related]
18. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
19. EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.
Yao W; Feng D; Bian W; Yang L; Li Y; Yang Z; Xiong Y; Zheng J; Zhai R; He J
Amino Acids; 2012 Nov; 43(5):2027-35. PubMed ID: 22476347
[TBL] [Abstract][Full Text] [Related]
20. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells.
Jiang C; Guo J; Wang Z; Xiao B; Lee HJ; Lee EO; Kim SH; Lu J
Breast Cancer Res; 2007; 9(6):R77. PubMed ID: 17986353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
